In gastric cancer, resistance to the vascular endothelial growth factor receptor 2 inhibitor apatinib is mediated by the expression of COL1A2, which, in turn, was regulated at the transcriptional level by EP300 and TWIST1 [114]. This evidence concerns the gene TWIST1 and gastric cancer.